Selected research
Industry Research
Antiretroviral Drug Industry Research Report 2026
Market perspective
The global Antiretroviral Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antiretroviral Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antiretroviral Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antiretroviral Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antiretroviral Drug include Boehringer-Ingelheim, Bristol-Myer Squibb, CIPLA, Gilead Sciences, ViiV Healthcare, AbbVie, Merck and Johnson and Johnson, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antiretroviral Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antiretroviral Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antiretroviral Drug Market by Company
Boehringer-Ingelheim
Bristol-Myer Squibb
CIPLA
Gilead Sciences
ViiV Healthcare
AbbVie
Merck
Johnson and Johnson
Antiretroviral Drug Segment by Type
Multi-Class Drugs Combination
Protease Inhibitors
NRTI
NNRTI
Other
Antiretroviral Drug Segment by Application
Hospital
Pharmaceutical Companies
Other
Antiretroviral Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiretroviral Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antiretroviral Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiretroviral Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antiretroviral Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Multi-Class Drugs Combination
- Protease Inhibitors
- NRTI
- NNRTI
- Other
Applications
- Hospital
- Pharmaceutical Companies
- Other
Companies covered
- Boehringer-Ingelheim
- Bristol-Myer Squibb
- CIPLA
- Gilead Sciences
- ViiV Healthcare
- AbbVie
- Merck
- Johnson and Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antiretroviral Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Multi-Class Drugs Combination
- 2.2.3 Protease Inhibitors
- 2.2.4 NRTI
- 2.2.5 NNRTI
- 2.2.6 Other
- 2.3 Antiretroviral Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Pharmaceutical Companies
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Antiretroviral Drug Breakdown Data by Type
- 3.1 Global Antiretroviral Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Antiretroviral Drug Forecasted Market Size by Type (2027-2032)
4 Antiretroviral Drug Breakdown Data by Application
- 4.1 Global Antiretroviral Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Antiretroviral Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antiretroviral Drug Market Perspective (2021-2032)
- 5.2 Global Antiretroviral Drug Growth Trends by Region
- 5.2.1 Global Antiretroviral Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antiretroviral Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Antiretroviral Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Antiretroviral Drug Market Dynamics
- 5.3.1 Antiretroviral Drug Industry Trends
- 5.3.2 Antiretroviral Drug Market Drivers
- 5.3.3 Antiretroviral Drug Market Challenges
- 5.3.4 Antiretroviral Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antiretroviral Drug Players by Revenue
- 6.1.1 Global Top Antiretroviral Drug Players by Revenue (2021-2026)
- 6.1.2 Global Antiretroviral Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Antiretroviral Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antiretroviral Drug Head Office and Area Served
- 6.4 Global Antiretroviral Drug Players, Product Type & Application
- 6.5 Global Antiretroviral Drug Manufacturers Established Date
- 6.6 Global Antiretroviral Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antiretroviral Drug Market Size (2021-2032)
- 7.2 North America Antiretroviral Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antiretroviral Drug Market Size by Country (2021-2026)
- 7.4 North America Antiretroviral Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antiretroviral Drug Market Size (2021-2032)
- 8.2 Europe Antiretroviral Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antiretroviral Drug Market Size by Country (2021-2026)
- 8.4 Europe Antiretroviral Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antiretroviral Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Antiretroviral Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antiretroviral Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antiretroviral Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antiretroviral Drug Market Size (2021-2032)
- 10.2 South America Antiretroviral Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antiretroviral Drug Market Size by Country (2021-2026)
- 10.4 South America Antiretroviral Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antiretroviral Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Antiretroviral Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antiretroviral Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antiretroviral Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Boehringer-Ingelheim
- 12.1.1 Boehringer-Ingelheim Company Information
- 12.1.2 Boehringer-Ingelheim Business Overview
- 12.1.3 Boehringer-Ingelheim Revenue in Antiretroviral Drug Business (2021-2026)
- 12.1.4 Boehringer-Ingelheim Antiretroviral Drug Product Portfolio
- 12.1.5 Boehringer-Ingelheim Recent Developments
- 12.2 Bristol-Myer Squibb
- 12.2.1 Bristol-Myer Squibb Company Information
- 12.2.2 Bristol-Myer Squibb Business Overview
- 12.2.3 Bristol-Myer Squibb Revenue in Antiretroviral Drug Business (2021-2026)
- 12.2.4 Bristol-Myer Squibb Antiretroviral Drug Product Portfolio
- 12.2.5 Bristol-Myer Squibb Recent Developments
- 12.3 CIPLA
- 12.3.1 CIPLA Company Information
- 12.3.2 CIPLA Business Overview
- 12.3.3 CIPLA Revenue in Antiretroviral Drug Business (2021-2026)
- 12.3.4 CIPLA Antiretroviral Drug Product Portfolio
- 12.3.5 CIPLA Recent Developments
- 12.4 Gilead Sciences
- 12.4.1 Gilead Sciences Company Information
- 12.4.2 Gilead Sciences Business Overview
- 12.4.3 Gilead Sciences Revenue in Antiretroviral Drug Business (2021-2026)
- 12.4.4 Gilead Sciences Antiretroviral Drug Product Portfolio
- 12.4.5 Gilead Sciences Recent Developments
- 12.5 ViiV Healthcare
- 12.5.1 ViiV Healthcare Company Information
- 12.5.2 ViiV Healthcare Business Overview
- 12.5.3 ViiV Healthcare Revenue in Antiretroviral Drug Business (2021-2026)
- 12.5.4 ViiV Healthcare Antiretroviral Drug Product Portfolio
- 12.5.5 ViiV Healthcare Recent Developments
- 12.6 AbbVie
- 12.6.1 AbbVie Company Information
- 12.6.2 AbbVie Business Overview
- 12.6.3 AbbVie Revenue in Antiretroviral Drug Business (2021-2026)
- 12.6.4 AbbVie Antiretroviral Drug Product Portfolio
- 12.6.5 AbbVie Recent Developments
- 12.7 Merck
- 12.7.1 Merck Company Information
- 12.7.2 Merck Business Overview
- 12.7.3 Merck Revenue in Antiretroviral Drug Business (2021-2026)
- 12.7.4 Merck Antiretroviral Drug Product Portfolio
- 12.7.5 Merck Recent Developments
- 12.8 Johnson and Johnson
- 12.8.1 Johnson and Johnson Company Information
- 12.8.2 Johnson and Johnson Business Overview
- 12.8.3 Johnson and Johnson Revenue in Antiretroviral Drug Business (2021-2026)
- 12.8.4 Johnson and Johnson Antiretroviral Drug Product Portfolio
- 12.8.5 Johnson and Johnson Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst